Enhanced anti-tumor effects by combination of tucatinib and radiation in HER2-overexpressing human cancer cell lines
Cancer Cell International,
Abstract Background Tucatinib (TUC), a HER2-directed tyrosine kinase inhibitor, is the first targeted drug demonstrating…